封面
市场调查报告书
商品编码
1504096

外科市场硬脑膜黏合剂 - 全球产业规模、份额、趋势、机会和预测,按应用、按类型(聚乙二醇、其他)、按形式、按地区和竞争细分,2019-2029F

Dural Adhesive Agent for Surgical Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application, By Type (Polyethylene glycol, Others ), By Form,By Region and Competition, 2019-2029F

出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2023 年,全球手术用硬脑膜黏合剂市场估值为1.8689 亿美元,预计在预测期内将出现令人印象深刻的成长,到2029 年复合年增长率为5.29%。合剂市场呈现出由对先进手术解决方案的需求不断增加。硬脑膜黏合剂在神经外科手术中发挥关键作用,有助于密封硬脑膜切口并最大限度地减少脑脊髓液渗漏。该市场受到多种因素的推动,包括脑肿瘤和脑外伤等神经系统疾病发生率的上升,需要进行手术干预。手术技术和材料的进步,加上对微创手术的日益青睐,有助于该市场的扩大。

市场概况
预测期 2025-2029
2023 年市场规模 1.8689亿美元
2029 年市场规模 2.5214亿美元
2024-2029 年复合年增长率 5.29%
成长最快的细分市场 颅脑外科
最大的市场 北美洲

主要市场参与者不断创新,开发具有增强性能的新型黏合剂,例如改善的生物相容性、更强的黏合强度和更快的固化时间,从而满足外科医生和患者不断变化的需求。新兴经济体越来越多地采用硬脑膜黏合剂,加上医疗基础设施的改善和医疗支出的增加,进一步推动了市场的成长。然而,产品审批的严格监管要求以及与先进手术技术相关的高成本等挑战对市场扩张构成了潜在的限制。儘管如此,市场参与者之间的策略合作、伙伴关係和收购,以及持续的研发工作,预计将在未来几年促进市场成长和创新。

主要市场驱动因素

神经系统疾病的发生率增加

手术技术的技术进步

主要市场挑战

开发和製造成本高

监管合规性和审批流程

主要市场趋势

对微创手术的偏好日益增长

强调以病人为中心的照护和提高手术效果

细分市场洞察

应用洞察

类型洞察

区域洞察

目录

第 1 章:产品概述

第 2 章:研究方法

第 3 章:执行摘要

第 4 章:客户之声

第 5 章:全球外科硬脑膜黏合剂市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依用途分类(颅脑外科、脊椎外科)
    • 依类型(聚乙二醇、其他(纤维蛋白胶))
    • 按形式(密封胶、密封膜)
    • 按公司划分 (2023)
    • 按地区
  • 市场地图

第 6 章:北美外科硬脑膜黏合剂市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按申请
    • 按类型
    • 按形式
    • 按国家/地区
  • 北美:国家分析
    • 美国
    • 墨西哥
    • 加拿大

第 7 章:欧洲外科硬脑膜黏合剂市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按申请
    • 按类型
    • 按形式
    • 按国家/地区
  • 欧洲:国家分析
    • 法国
    • 德国
    • 英国
    • 义大利
    • 西班牙

第 8 章:亚太地区外科硬脑膜黏合剂市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按申请
    • 按类型
    • 按形式
    • 按国家/地区
  • 亚太地区:国家分析
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲

第 9 章:南美洲外科硬脑膜黏合剂市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按申请
    • 按类型
    • 按形式
    • 按国家/地区
  • 南美洲:国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第10章:中东和非洲外科硬脑膜黏合剂市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按申请
    • 按类型
    • 按形式
    • 按国家/地区
  • MEA:国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章:市场动态

  • 司机
  • 挑战

第 12 章:市场趋势与发展

  • 併购(如有)
  • 产品发布(如有)
  • 最近的发展

第 13 章:波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第14章:竞争格局

  • Medprin Biotech GmbH
  • Integra LifeSciences Corporation
  • Pramand LLC
  • Stryker Corporation
  • DuraStat, Inc.
  • Medtronic plc
  • Becton, Dickinson and Company
  • Regenity Biosciences
  • Baxter International, Inc.
  • Johnson & Johnson

第 15 章:策略建议

第16章调查会社について・免责事项

简介目录
Product Code: 24109

Global Dural Adhesive Agent for Surgical Market was valued at USD 186.89 Million in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 5.29% through 2029. The Global Dural Adhesive Agent for Surgical Market encompasses a dynamic landscape driven by the increasing demand for advanced surgical solutions. Dural adhesive agents play a pivotal role in neurosurgical procedures, aiding in the sealing of dural incisions and minimizing cerebrospinal fluid leakage. This market is propelled by several factors, including the rising incidence of neurological disorders, such as brain tumors and traumatic brain injuries, necessitating surgical intervention. Advancements in surgical techniques and materials, coupled with the growing preference for minimally invasive procedures, contribute to the expansion of this market.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 186.89 Million
Market Size 2029USD 252.14 Million
CAGR 2024-20295.29%
Fastest Growing SegmentCranial Surgery
Largest MarketNorth America

Key market players continuously innovate to develop novel adhesive agents with enhanced properties, such as improved biocompatibility, stronger adhesive strength, and faster curing times, thereby addressing the evolving needs of surgeons and patients alike. The increasing adoption of dural adhesive agents in emerging economies, alongside improving healthcare infrastructure and growing healthcare expenditure, further drives market growth. However, challenges such as stringent regulatory requirements for product approval and the high cost associated with advanced surgical technologies pose potential restraints to market expansion. Nevertheless, strategic collaborations, partnerships, and acquisitions among market players, along with ongoing research and development efforts, are anticipated to foster market growth and innovation in the forthcoming years.

Key Market Drivers

Increasing Incidence of Neurological Disorders

The increasing incidence of neurological disorders is a significant driver behind the growing demand for dural adhesive agents in the surgical market. Across the globe, neurological disorders such as brain tumors, traumatic brain injuries (TBIs), stroke, epilepsy, and neurodegenerative diseases like Alzheimer's and Parkinson's are on the rise. This trend is primarily attributed to several factors, including population aging, lifestyle changes, environmental factors, and improved diagnostic capabilities.

As populations age, the prevalence of neurological disorders tends to increase, as many of these conditions are more common in older individuals. Lifestyle factors such as sedentary lifestyles, poor dietary habits, and increasing urbanization contribute to the incidence of neurological diseases like stroke and dementia. Environmental factors such as pollution and exposure to toxins may also play a role in the development of certain neurological disorders. Advancements in medical imaging technologies and diagnostic techniques have led to earlier and more accurate detection of neurological conditions, further contributing to the observed increase in incidence rates. With improved access to healthcare and greater awareness of neurological disorders, more cases are being diagnosed and treated, driving the demand for neurosurgical interventions, including procedures that require dural adhesive agents.

In response to this growing burden of neurological diseases, healthcare systems worldwide are investing in neurosurgical capabilities, including the adoption of advanced surgical techniques and technologies. Consequently, the demand for dural adhesive agents is expected to continue to rise in tandem with the increasing incidence of neurological disorders, presenting significant opportunities for market growth and innovation in the neurosurgical sector.

Technological Advancements in Surgical Techniques

The growing preference for minimally invasive procedures represents a paradigm shift in surgical practice, driven by the desire to reduce patient trauma, enhance recovery times, and improve overall surgical outcomes. In neurosurgery, this trend has gained momentum, leading to the widespread adoption of minimally invasive techniques for various conditions, including brain tumors, vascular malformations, and spinal disorders. One of the primary advantages of minimally invasive neurosurgery is the reduced disruption to surrounding tissues and structures. Unlike traditional open surgeries, which require large incisions and extensive tissue dissection, minimally invasive procedures involve smaller incisions and the use of specialized instruments, such as endoscopes and microscopes, to access the surgical site. This results in less blood loss, decreased postoperative pain, and faster recovery times for patients.

Minimally invasive techniques offer enhanced precision and visualization, enabling surgeons to target pathology with greater accuracy while minimizing damage to healthy tissue. Techniques such as endoscopic skull base surgery and minimally invasive spine surgery allow for access to deep-seated lesions and complex anatomical regions with minimal disturbance to surrounding structures. Advancements in imaging technologies, such as intraoperative MRI and neuronavigation systems, provide real-time feedback to surgeons, further enhancing the safety and efficacy of minimally invasive procedures. Another significant benefit of minimally invasive neurosurgery is the potential for shorter hospital stays and reduced healthcare costs. By minimizing tissue trauma and postoperative complications, patients undergoing minimally invasive procedures may experience quicker recoveries and require less intensive postoperative care, leading to cost savings for healthcare systems and insurers.

The growing preference for minimally invasive procedures in neurosurgery reflects a commitment to delivering high-quality, patient-centered care. As technological innovations continue to advance and surgeons gain more experience with these techniques, the demand for minimally invasive neurosurgical procedures is expected to increase, driving further improvements in patient outcomes and quality of life. This trend will continue to shape the landscape of neurosurgery, with implications for the development and adoption of adjunctive technologies such as dural adhesive agents.

Key Market Challenges

High Development and Manufacturing Costs

The development and manufacturing of dural adhesive agents incur substantial expenses throughout the product lifecycle. Research and development (R&D) activities involve extensive investment in scientific research, formulation development, and preclinical studies to identify and optimize suitable adhesive formulations. Subsequently, clinical trials are conducted to assess the safety and efficacy of the product in human subjects, which require significant financial resources for patient recruitment, data collection, and regulatory compliance.

Obtaining regulatory approvals from agencies such as the FDA and EMA adds another layer of cost, as companies must adhere to stringent regulatory requirements and guidelines. This process involves compiling comprehensive data on product safety, efficacy, and quality, as well as conducting audits and inspections to ensure compliance with Good Manufacturing Practices (GMP) standards. Maintaining consistent product quality and adhering to GMP standards necessitate ongoing investments in manufacturing facilities, equipment, and personnel training. Quality control measures, such as batch testing and quality assurance protocols, incur additional expenses to ensure product integrity and compliance with regulatory standards.

The high upfront and operational costs associated with dural adhesive agent development and manufacturing pose significant barriers to entry for smaller companies and startups. Limited financial resources may hinder their ability to compete with larger established players, thereby limiting innovation and market competitiveness.

Regulatory Compliance and Approval Processes

Navigating the regulatory compliance and approval processes presents a formidable challenge for companies operating in the Dural Adhesive Agent for Surgical market. Regulatory agencies such as the FDA in the United States and the European Medicines Agency (EMA) in Europe have established stringent requirements to ensure the safety, efficacy, and quality assurance of medical devices and surgical products, including dural adhesive agents.Obtaining regulatory approval for new dural adhesive agents involves a comprehensive evaluation process, which typically includes rigorous preclinical and clinical testing. These studies are designed to demonstrate the product's safety profile, effectiveness in sealing dural defects, and compatibility with human tissues. The process can be time-consuming and resource-intensive, requiring significant investments in research and development.

The regulatory landscape is further complicated by variations in requirements across different regions and countries. Companies seeking global market access must navigate a maze of regulatory frameworks, each with its own set of requirements and procedures. Adhering to these requirements adds another layer of complexity and increases the time and resources needed to bring a product to market.

Failure to meet regulatory standards can have serious consequences for companies, including delays in product launch, regulatory sanctions, or even product recalls. These setbacks not only impact market entry but also erode investor confidence and damage brand reputation, leading to significant financial losses and long-term implications for profitability.

Key Market Trends

Growing Preference for Minimally Invasive Procedures

The growing preference for minimally invasive procedures signifies a transformative shift in surgical practice, driven by a convergence of factors that prioritize patient well-being, technological advancements, and healthcare efficiency, thus boosting the Dural Adhesive Agent for Surgical marketb. Minimally invasive techniques have garnered widespread acceptance across various surgical specialties, including neurosurgery, owing to their numerous benefits for both patients and healthcare providers.

Unlike traditional open surgeries, which often require large incisions and extensive tissue manipulation, minimally invasive procedures entail smaller incisions and specialized instruments, allowing surgeons to access the surgical site with minimal disruption to surrounding tissues. This approach translates into reduced postoperative pain, decreased blood loss, shorter hospital stays, and faster return to normal activities for patients. Minimally invasive techniques offer enhanced precision and accuracy, enabling surgeons to navigate complex anatomical structures with greater finesse. Advanced imaging modalities, such as intraoperative MRI and computer-assisted navigation systems, provide real-time visualization and guidance, further enhancing the safety and efficacy of minimally invasive procedures. Techniques like endoscopy and laparoscopy afford surgeons a magnified view of the surgical field, facilitating meticulous tissue dissection and precise manipulation of surgical instruments.

The shift towards minimally invasive procedures also carries significant implications for healthcare economics and resource utilization. By reducing the length of hospital stays, minimizing postoperative complications, and accelerating patient recovery, minimally invasive surgeries contribute to cost savings for healthcare systems and insurers. The ability to perform procedures in outpatient settings or ambulatory surgery centers enhances healthcare efficiency and patient access to timely care.

Emphasis on Patient-Centric Care and Enhanced Surgical Outcomes

In today's healthcare landscape, the shift towards patient-centric care is reshaping surgical practice, with a renewed focus on optimizing patient outcomes and enhancing the overall quality of care. Dural adhesive agents play a pivotal role in this paradigm, offering surgeons a valuable tool to achieve secure dural closure and minimize postoperative complications. By effectively sealing dural defects and preventing cerebrospinal fluid leaks, dural adhesive agents contribute to smoother recovery experiences for patients undergoing neurosurgical procedures. Reduced complications translate to shorter hospital stays, decreased healthcare costs, and improved patient satisfaction, aligning with the goals of value-based healthcare delivery.

The adoption of dural adhesive agents reflects healthcare providers' commitment to adopting innovative solutions that prioritize patient well-being and safety. Surgeons recognize the importance of leveraging advanced technologies and techniques to enhance surgical outcomes and minimize patient discomfort. As healthcare systems continue to evolve towards value-based reimbursement models, the demand for products and technologies that offer demonstrable benefits in terms of patient outcomes and healthcare efficiency is expected to grow. Dural adhesive agents represent a prime example of this trend, with their ability to streamline surgical procedures, reduce complications, and improve patient satisfaction.

The emphasis on patient-centric care underscores the importance of patient education and engagement. Healthcare providers play a crucial role in educating patients about the benefits of dural adhesive agents and involving them in shared decision-making processes regarding their treatment options. This collaborative approach fosters trust, empowers patients to take an active role in their care, and ultimately leads to better treatment outcomes and patient experiences.

Segmental Insights

Application Insights

Based on the Application, In 2023, the cranial surgery segment emerged as the dominant segment in the global dural adhesive agent for surgical market. Cranial surgery encompasses a wide range of procedures aimed at treating conditions such as brain tumors, traumatic brain injuries, vascular malformations, and intracranial hemorrhages. These conditions often require meticulous surgical intervention to achieve hemostasis, remove pathological tissue, and repair dural defects. Dural adhesive agents play a critical role in cranial surgery by facilitating secure dural closure, minimizing cerebrospinal fluid leakage, and reducing the risk of postoperative complications.

Advancements in neuroimaging technologies, surgical techniques, and perioperative care have expanded the scope and complexity of cranial surgeries. Minimally invasive approaches, such as endoscopic skull base surgery and image-guided neurosurgery, have become increasingly common, driving the demand for specialized dural adhesive agents that can accommodate these innovative techniques. The rising incidence of neurological disorders, coupled with increasing awareness and access to neurosurgical interventions, has further bolstered the demand for dural adhesive agents in cranial surgery. As populations age and lifestyles change, the prevalence of conditions such as brain tumors and cerebrovascular diseases continues to rise, necessitating a greater volume of cranial surgeries worldwide.

Type Insights

Based on the Type, in 2023, the Others segment, particularly fibrin glue, emerged as the dominant segment in the global dural adhesive agent for surgical market. This dominance can be attributed to several key factors that underscore the unique advantages of fibrin glue in neurosurgical applications. Fibrin glue, a biological adhesive derived from human plasma proteins, offers several distinct benefits that make it well-suited for dural closure and sealing in surgical procedures. One of its primary advantages is its biocompatibility, as fibrin glue closely resembles the body's natural clotting mechanism and is less likely to elicit an immune response or adverse reactions. This property is particularly crucial in delicate neurosurgical procedures, where minimizing tissue inflammation and foreign body reactions is paramount.

Fibrin glue demonstrates excellent adhesive properties, allowing for secure and reliable dural closure without the need for sutures or staples. Its ability to adhere rapidly to tissue surfaces, form a strong bond, and provide hemostasis contributes to its widespread adoption in cranial and spinal surgeries. Fibrin glue promotes tissue healing and regeneration by serving as a scaffold for cell migration and proliferation, further enhancing its efficacy in promoting optimal surgical outcomes.

Regional Insights

In 2023, North America solidified its position as the dominant region in the global dural adhesive agent for surgical market, holding the largest market share. North America boasts a well-established healthcare ecosystem characterized by advanced medical facilities, renowned research institutions, and a strong regulatory framework. The presence of leading healthcare providers and academic medical centers specializing in neurosurgery fosters innovation and collaboration in the development and adoption of dural adhesive agents.

The region is at the forefront of technological advancements in neurosurgical techniques, imaging modalities, and surgical instrumentation. Surgeons in North America have access to state-of-the-art equipment and cutting-edge technologies, enabling them to perform complex neurosurgical procedures with precision and efficacy. This technological sophistication extends to the use of dural adhesive agents, where innovative formulations and delivery systems are continuously introduced to optimize surgical outcomes. The high prevalence of neurological disorders in North America contributes to the significant demand for neurosurgical interventions, including procedures that require dural adhesive agents. Conditions such as brain tumors, traumatic brain injuries, and spinal cord injuries are prevalent in the region, driving the need for effective dural closure and sealing solutions.

Key Market Players

Medprin Biotech GmbH

Integra LifeSciences Corporation

Pramand LLC

Stryker Corporation

DuraStat, Inc.

Medtronic plc

Becton, Dickinson and Company

Regenity Biosciences

Baxter International, Inc.

Johnson & Johnson

Report Scope:

In this report, the Global Dural Adhesive Agent for Surgical Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Dural Adhesive Agent for Surgical Market, By Application:

    Cranial Surgery Spinal Surgery

Dural Adhesive Agent for Surgical Market, By Type:

    Polyethylene glycol Others (Fibrin Glue)

Dural Adhesive Agent for Surgical Market, By Form:

    Sealant Glue Sealant Film

Dural Adhesive Agent for Surgical Market, By Region:

    North America

United States

Canada

Mexico

    Europe

France

United Kingdom

Italy

Germany

Spain

    Asia-Pacific

China

India

Japan

Australia

South Korea

    South America

Brazil

Argentina

Colombia

    Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Dural Adhesive Agent for Surgical Market.

Available Customizations:

Global Dural Adhesive Agent for Surgical market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Dural Adhesive Agent for Surgical Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Application(Cranial Surgery, Spinal Surgery)
    • 5.2.2. By Type (Polyethylene glycol, Others (Fibrin Glue))
    • 5.2.3. By Form (Sealant Glue, Sealant Film)
    • 5.2.4. By Company (2023)
    • 5.2.5. By Region
  • 5.3. Market Map

6. North America Dural Adhesive Agent for Surgical Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Application
    • 6.2.2. By Type
    • 6.2.3. By Form
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Dural Adhesive Agent for Surgical Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Application
        • 6.3.1.2.2. By Type
        • 6.3.1.2.3. By Form
    • 6.3.2. Mexico Dural Adhesive Agent for Surgical Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Application
        • 6.3.2.2.2. By Type
        • 6.3.2.2.3. By Form
    • 6.3.3. Canada Dural Adhesive Agent for Surgical Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Application
        • 6.3.3.2.2. By Type
        • 6.3.3.2.3. By Form

7. Europe Dural Adhesive Agent for Surgical Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Application
    • 7.2.2. By Type
    • 7.2.3. By Form
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Dural Adhesive Agent for Surgical Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Application
        • 7.3.1.2.2. By Type
        • 7.3.1.2.3. By Form
    • 7.3.2. Germany Dural Adhesive Agent for Surgical Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Application
        • 7.3.2.2.2. By Type
        • 7.3.2.2.3. By Form
    • 7.3.3. United Kingdom Dural Adhesive Agent for Surgical Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Application
        • 7.3.3.2.2. By Type
        • 7.3.3.2.3. By Form
    • 7.3.4. Italy Dural Adhesive Agent for Surgical Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Application
        • 7.3.4.2.2. By Type
        • 7.3.4.2.3. By Form
    • 7.3.5. Spain Dural Adhesive Agent for Surgical Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Application
        • 7.3.5.2.2. By Type
        • 7.3.5.2.3. By Form

8. Asia-Pacific Dural Adhesive Agent for Surgical Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Application
    • 8.2.2. By Type
    • 8.2.3. By Form
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Dural Adhesive Agent for Surgical Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Application
        • 8.3.1.2.2. By Type
        • 8.3.1.2.3. By Form
    • 8.3.2. India Dural Adhesive Agent for Surgical Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Application
        • 8.3.2.2.2. By Type
        • 8.3.2.2.3. By Form
    • 8.3.3. South Korea Dural Adhesive Agent for Surgical Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Application
        • 8.3.3.2.2. By Type
        • 8.3.3.2.3. By Form
    • 8.3.4. Japan Dural Adhesive Agent for Surgical Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Application
        • 8.3.4.2.2. By Type
        • 8.3.4.2.3. By Form
    • 8.3.5. Australia Dural Adhesive Agent for Surgical Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Application
        • 8.3.5.2.2. By Type
        • 8.3.5.2.3. By Form

9. South America Dural Adhesive Agent for Surgical Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Application
    • 9.2.2. By Type
    • 9.2.3. By Form
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Dural Adhesive Agent for Surgical Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Application
        • 9.3.1.2.2. By Type
        • 9.3.1.2.3. By Form
    • 9.3.2. Argentina Dural Adhesive Agent for Surgical Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Application
        • 9.3.2.2.2. By Type
        • 9.3.2.2.3. By Form
    • 9.3.3. Colombia Dural Adhesive Agent for Surgical Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Application
        • 9.3.3.2.2. By Type
        • 9.3.3.2.3. By Form

10. Middle East and Africa Dural Adhesive Agent for Surgical Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Application
    • 10.2.2. By Type
    • 10.2.3. By Form
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Dural Adhesive Agent for Surgical Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Application
        • 10.3.1.2.2. By Type
        • 10.3.1.2.3. By Form
    • 10.3.2. Saudi Arabia Dural Adhesive Agent for Surgical Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Application
        • 10.3.2.2.2. By Type
        • 10.3.2.2.3. By Form
    • 10.3.3. UAE Dural Adhesive Agent for Surgical Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Application
        • 10.3.3.2.2. By Type
        • 10.3.3.2.3. By Form

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porters Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Medprin Biotech GmbH
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Integra LifeSciences Corporation
  • 14.3. Pramand LLC
  • 14.4. Stryker Corporation
  • 14.5. DuraStat, Inc.
  • 14.6. Medtronic plc
  • 14.7. Becton, Dickinson and Company
  • 14.8. Regenity Biosciences
  • 14.9. Baxter International, Inc.
  • 14.10. Johnson & Johnson

15. Strategic Recommendations

16. About Us & Disclaimer